What is Precision Epigenomics?
Precision Epigenomics operates at the intersection of biotechnology and preventative medicine, specializing in the development of high-sensitivity liquid biopsy assays. The company's flagship EPISEEK platform is engineered to detect multiple cancer types during their nascent stages, offering a non-invasive alternative to traditional diagnostic procedures. By prioritizing affordability and diagnostic reliability, the firm aims to democratize access to high-precision oncology screening, effectively shifting the paradigm from reactive treatment to proactive health management. Its market position is defined by a commitment to clinical excellence and the integration of scalable, high-throughput laboratory processes.
How much funding has Precision Epigenomics raised?
Precision Epigenomics has raised a total of $4.2M across 3 funding rounds:
Other Financing Round
$2.4M
Series A
$1.5M
Debt
$265K
Series A (2024): $1.5M with participation from Shaffer Capital
Other Financing Round (2024): $2.4M, investors not publicly disclosed
Debt (2025): $265K, investors not publicly disclosed
Key Investors in Precision Epigenomics
Shaffer Capital
Shaffer Capital is a financial services firm providing comprehensive investment management and retirement planning, focusing on customized strategies that promote long-term capital growth.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Precision Epigenomics?
With the recent influx of capital, Precision Epigenomics is positioned to scale its operational infrastructure and expand its clinical validation studies. The strategic deployment of these funds will likely focus on enhancing the sensitivity of the EPISEEK test, broadening its diagnostic panel, and navigating the complex regulatory pathways required for widespread clinical adoption. As the company transitions into a more mature phase of its lifecycle, the focus will shift toward establishing strategic partnerships with healthcare providers and diagnostic laboratories to integrate its technology into standard patient care workflows. This phase of growth is critical for establishing long-term market dominance in the rapidly evolving liquid biopsy sector.
See full Precision Epigenomics company page
